Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Income from Continuing Operations data on record, last reported at 9834000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 75.13% year-over-year to 9834000.0; the TTM value through Sep 2025 reached 41246000.0, up 24.74%, while the annual FY2023 figure was 23407000.0, 28.12% up from the prior year.
  • Income from Continuing Operations reached 9834000.0 in Q3 2025 per CRVS's latest filing, down from 7609000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15732000.0 in Q1 2025 and bottomed at 39535000.0 in Q3 2024.
  • Average Income from Continuing Operations over 4 years is 7541428.57, with a median of 6039500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 669.91% in 2024, then surged 364.98% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 5666000.0 in 2022, then grew by 0.26% to 5651000.0 in 2023, then tumbled by 599.61% to 39535000.0 in 2024, then soared by 75.13% to 9834000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 9834000.0 in Q3 2025, 7609000.0 in Q2 2025, and 15732000.0 in Q1 2025.